Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

6.0K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.0K
Drug Distribution: Volume of Distribution01:25

Drug Distribution: Volume of Distribution

7.6K
The volume of distribution refers to the theoretical volume necessary to contain the entire amount of an administered drug at the same concentration observed in the blood plasma. The body's intracellular fluid compartment, which makes up two-thirds of the total body water, is contrasted with the extracellular fluid compartment—comprising plasma and interstitial fluid—that accounts for one-third. The volume of distribution can vary depending on the characteristics of the drug.
7.6K
F Distribution01:19

F Distribution

10.7K
The F distribution was named after Sir Ronald Fisher, an English statistician. The F statistic is a ratio (a fraction) with two sets of degrees of freedom; one for the numerator and one for the denominator. The F distribution is derived from the Student's t distribution. The values of the F distribution are squares of the corresponding values of the t distribution. One-Way ANOVA expands the t test for comparing more than two groups. The scope of that derivation is beyond the level of this...
10.7K
Distributed Loads01:19

Distributed Loads

981
Distributed loads are a common type of load that engineers and scientists encounter in various practical situations. Distributed loads often refer to a type of load spread over a surface or a structure and can be modeled as continuous force per unit area.
For example, consider a bookshelf filled with books stacked vertically adjacent to each other. The weight of the books is evenly distributed over the length of the shelf. As a result, the pressure at different locations on the surface of the...
981
Volume of Distribution01:20

Volume of Distribution

1.4K
The apparent volume of distribution (Vd) is a crucial pharmacokinetic parameter representing the hypothetical body fluid volume into which a drug disperses. It is calculated based on the total amount of drug in the body (estimated from the administered dose and bioavailability) divided by the plasma drug concentration. The total amount of drug in the body does not directly refer to the dose given but is derived by accounting for absorption, distribution, metabolism, and excretion processes.
1.4K
Uniform Distribution01:19

Uniform Distribution

6.1K
The uniform distribution is a continuous probability distribution of events with an equal probability of occurrence. This distribution is rectangular.
Two essential properties of this distribution are
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Metabolic Risk in Childhood Brain Cancer Survivors with Childhood-Onset Growth Hormone Deficiency.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same author

Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.

Nature medicine·2026
Same author

Usefulness OF SOX10 immunohistochemistry for subtyping diffuse midline gliomas EGFR-altered.

Acta neuropathologica communications·2026
Same author

AMBRA1 enhances Sonic Hedgehog signaling during cerebellar development and in medulloblastoma.

Developmental cell·2026
Same author

Microsurgical Resection of Subependymal Giant Cell Astrocytoma: Single-Center Retrospective Analysis and Meta-Analysis.

Neurosurgery·2026
Same author

H3K27ME3 loss in diffuse midline gliomas lacking H3K27M or EZHIP expressions, a potential diagnostic pitfall!

Acta neuropathologica·2026

Related Experiment Video

Updated: Feb 14, 2026

Monitoring Blood-Brain Barrier Opening in Rats with a Preclinical Focused Ultrasound System
03:32

Monitoring Blood-Brain Barrier Opening in Rats with a Preclinical Focused Ultrasound System

Published on: September 13, 2024

1.3K

Ibrutinib brain distribution: a preclinical study.

Lauriane Goldwirt1,2, Kevin Beccaria3, Alain Ple4

  • 1Pharmacology Department, Saint-Louis Hospital, AP-HP, 1 Avenue Claude Vellefaux, 75010, Paris, France. lauriane.goldwirt@aphp.fr.

Cancer Chemotherapy and Pharmacology
|February 25, 2018
PubMed
Summary
This summary is machine-generated.

Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, effectively crosses the blood-brain barrier (BBB) in mice. This brain penetration supports its use in treating central nervous system (CNS) involvement in lymphomas like MCL and CLL.

Keywords:
Brain distributionCNS localizationIbrutinibPharmacokinetics

More Related Videos

Brain Source Imaging in Preclinical Rat Models of Focal Epilepsy using High-Resolution EEG Recordings
08:20

Brain Source Imaging in Preclinical Rat Models of Focal Epilepsy using High-Resolution EEG Recordings

Published on: June 6, 2015

15.9K
Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models
07:21

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models

Published on: June 30, 2021

7.2K

Related Experiment Videos

Last Updated: Feb 14, 2026

Monitoring Blood-Brain Barrier Opening in Rats with a Preclinical Focused Ultrasound System
03:32

Monitoring Blood-Brain Barrier Opening in Rats with a Preclinical Focused Ultrasound System

Published on: September 13, 2024

1.3K
Brain Source Imaging in Preclinical Rat Models of Focal Epilepsy using High-Resolution EEG Recordings
08:20

Brain Source Imaging in Preclinical Rat Models of Focal Epilepsy using High-Resolution EEG Recordings

Published on: June 6, 2015

15.9K
Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models
07:21

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models

Published on: June 30, 2021

7.2K

Area of Science:

  • Pharmacology
  • Neuro-oncology
  • Drug Discovery

Background:

  • Central nervous system (CNS) involvement occurs in 4-4.1% of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) patients.
  • Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, shows efficacy in CNS lymphomas.
  • Drug distribution across the blood-brain barrier (BBB) is crucial for CNS treatment efficacy.

Purpose of the Study:

  • To investigate the brain distribution of ibrutinib in a mouse model.
  • To determine if ibrutinib can cross the BBB and achieve therapeutic concentrations in the brain.

Main Methods:

  • Pharmacokinetic studies of ibrutinib in plasma and brain of healthy mice.
  • Single and multiple-dose studies evaluating ibrutinib accumulation in brain structures.
  • Quantification using validated liquid-chromatography mass spectrometry.

Main Results:

  • Ibrutinib rapidly crosses the BBB, with maximal concentrations in plasma and brain being similar.
  • Brain exposure to ibrutinib is dose-dependent and correlates with plasma exposure.
  • A brain-to-plasma AUC ratio of 0.7 was observed, with accumulation in the ventricular area.

Conclusions:

  • Ibrutinib demonstrates significant brain distribution, supporting its clinical use for CNS manifestations of MCL, CLL, and PCNSL.
  • The findings validate ibrutinib's potential as a therapeutic agent for primary and secondary CNS lymphomas.